Finally, FC treatment during CKD had no detrimental effects on skeletal mineral matrix composition or maturity, and FC treatment in the absence of FGF23 revealed potential FGF23‐protective actions on bone. The gene discussed is FGF23; the disease is chronic kidney disease.